×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
CORT – corcept therapeutics incorporated (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
CORT
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/16
08:07 am
cort
Corcept's Phase 3 Long-Term Extension Study of Relacorilant Demonstrated Durable Cardiometabolic Improvements in Patients with Hypercortisolism [Yahoo! Finance]
Low
Report
Corcept's Phase 3 Long-Term Extension Study of Relacorilant Demonstrated Durable Cardiometabolic Improvements in Patients with Hypercortisolism [Yahoo! Finance]
12/16
08:00 am
cort
Corcept’s Phase 3 Long-Term Extension Study of Relacorilant Demonstrated Durable Cardiometabolic Improvements in Patients with Hypercortisolism
Medium
Report
Corcept’s Phase 3 Long-Term Extension Study of Relacorilant Demonstrated Durable Cardiometabolic Improvements in Patients with Hypercortisolism
12/12
04:05 pm
cort
Corcept Announces Positive Results in Treatment Phase of CATALYST Trial in Patients With Hypercortisolism (Cushing’s Syndrome) and Difficult-to-Control Diabetes
Medium
Report
Corcept Announces Positive Results in Treatment Phase of CATALYST Trial in Patients With Hypercortisolism (Cushing’s Syndrome) and Difficult-to-Control Diabetes
12/11
04:19 pm
cort
Corcept Announces Results From Phase 2 Study of Dazucorilant in Patients With Amyotrophic Lateral Sclerosis (ALS) [Yahoo! Finance]
Medium
Report
Corcept Announces Results From Phase 2 Study of Dazucorilant in Patients With Amyotrophic Lateral Sclerosis (ALS) [Yahoo! Finance]
12/11
04:05 pm
cort
Corcept Announces Results From Phase 2 Study of Dazucorilant in Patients With Amyotrophic Lateral Sclerosis (ALS)
Low
Report
Corcept Announces Results From Phase 2 Study of Dazucorilant in Patients With Amyotrophic Lateral Sclerosis (ALS)
12/3
08:23 am
cort
Corcept Therapeutics (NASDAQ:CORT) shareholders have earned a 34% CAGR over the last five years [Yahoo! Finance]
Low
Report
Corcept Therapeutics (NASDAQ:CORT) shareholders have earned a 34% CAGR over the last five years [Yahoo! Finance]
11/29
01:00 pm
cort
Corcept (CORT) Up 19.7% Since Last Earnings Report: Can It Continue? [Yahoo! Finance]
Neutral
Report
Corcept (CORT) Up 19.7% Since Last Earnings Report: Can It Continue? [Yahoo! Finance]
11/26
12:06 am
cort
Corcept Therapeutics Incorporated (NASDAQ: CORT) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
Low
Report
Corcept Therapeutics Incorporated (NASDAQ: CORT) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
Date
Time
Symbol
Company Name
Action
%Chg
10/30/2024
04:05 pm
CORT
corcept therapeutics incorporated
BEAT
Report
1.0%
corcept therapeutics incorporated
7/29/2024
04:05 pm
CORT
corcept therapeutics incorporated
BEAT
Report
3.9%
corcept therapeutics incorporated
5/1/2024
04:05 pm
CORT
corcept therapeutics incorporated
BEAT
Report
4.9%
corcept therapeutics incorporated
2/15/2024
04:07 pm
CORT
corcept therapeutics incorporated
BEAT
Report
-9.2%
corcept therapeutics incorporated
Date
Time
Symbol
Headline
Impact
12/12
04:59 pm
cort
Form 4 CORCEPT THERAPEUTICS For: Dec 10 Filed by: Swisher Daniel N JR
Low
Report
Form 4 CORCEPT THERAPEUTICS For: Dec 10 Filed by: Swisher Daniel N JR
12/10
10:00 am
cort
Form 144 CORCEPT THERAPEUTICS Filed by: Swisher Daniel N JR
Low
Report
Form 144 CORCEPT THERAPEUTICS Filed by: Swisher Daniel N JR
12/4
08:03 pm
cort
Form 4 CORCEPT THERAPEUTICS For: Dec 02 Filed by: Guyer William
Medium
Report
Form 4 CORCEPT THERAPEUTICS For: Dec 02 Filed by: Guyer William
12/4
07:52 pm
cort
Form 4 CORCEPT THERAPEUTICS For: Dec 02 Filed by: Maduck Sean
Medium
Report
Form 4 CORCEPT THERAPEUTICS For: Dec 02 Filed by: Maduck Sean
12/4
07:42 pm
cort
Form 4 CORCEPT THERAPEUTICS For: Dec 02 Filed by: Robb Gary Charles
Medium
Report
Form 4 CORCEPT THERAPEUTICS For: Dec 02 Filed by: Robb Gary Charles
12/4
07:41 pm
cort
Form 4 CORCEPT THERAPEUTICS For: Dec 02 Filed by: Lyon Joseph Douglas
Medium
Report
Form 4 CORCEPT THERAPEUTICS For: Dec 02 Filed by: Lyon Joseph Douglas
12/4
07:34 pm
cort
Form 4 CORCEPT THERAPEUTICS For: Dec 02 Filed by: Mokari Atabak
Medium
Report
Form 4 CORCEPT THERAPEUTICS For: Dec 02 Filed by: Mokari Atabak
11/26
06:17 pm
cort
Form 4 CORCEPT THERAPEUTICS For: Nov 22 Filed by: Robb Gary Charles
Low
Report
Form 4 CORCEPT THERAPEUTICS For: Nov 22 Filed by: Robb Gary Charles
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
8/1
Q2/2019 6/30/2019 EPS 0.250 ZacksConsensus 0.180 ActVsEst 0.070 - Beat
14.1%
11/8 Corcept Therapeutics' (CORT) CEO Joseph Belanoff on Q3 2019 Results - Earnings Call Transcript [Seeking Alpha] 9.1%
4/17 Corcept Therapeutics Incorporated (NASDAQ: CORT) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 5.4%
2/28 Form 4 CORCEPT THERAPEUTICS For: Feb 26 Filed by: BELANOFF JOSEPH K 4.8%
3/13 Form 8-K CORCEPT THERAPEUTICS For: Mar 12 3.1%
9/24 Corcept Therapeutics Incorporated (NASDAQ: CORT) is now covered by analysts at Jefferies Financial Group Inc. They set a "buy" rating on the stock. 3.0%
5/14 Corcept Therapeutics Incorporated (NASDAQ: CORT) was downgraded by analysts at TheStreet from a "b" rating to a "c+" rating. 2.9%
11/7 Q3/2019 9/30/2019 EPS 0.310 ZacksConsensus 0.190 ActVsEst 0.120 - Beat 2.8%
5/23 Corcept Therapeutics Incorporated (NASDAQ: CORT) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 2.7%
4/2 Corcept Therapeutics Incorporated (NASDAQ: CORT) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. 2.7%
11/8 Corcept Therapeutics' (CORT) CEO Joseph Belanoff on Q3 2019 Results - Earnings Call Transcript [Seeking Alpha] 9.1%
4/17 Corcept Therapeutics Incorporated (NASDAQ: CORT) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 5.4%
2/28 Form 4 CORCEPT THERAPEUTICS For: Feb 26 Filed by: BELANOFF JOSEPH K 4.8%
3/13 Form 8-K CORCEPT THERAPEUTICS For: Mar 12 3.1%
9/24 Corcept Therapeutics Incorporated (NASDAQ: CORT) is now covered by analysts at Jefferies Financial Group Inc. They set a "buy" rating on the stock. 3.0%
5/14 Corcept Therapeutics Incorporated (NASDAQ: CORT) was downgraded by analysts at TheStreet from a "b" rating to a "c+" rating. 2.9%
11/7 Q3/2019 9/30/2019 EPS 0.310 ZacksConsensus 0.190 ActVsEst 0.120 - Beat 2.8%
5/23 Corcept Therapeutics Incorporated (NASDAQ: CORT) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 2.7%
4/2 Corcept Therapeutics Incorporated (NASDAQ: CORT) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. 2.7%
TOP News Decliners
3/5
Form 5 CORCEPT THERAPEUTICS For: Dec 31 Filed by: BAKER G LEONARD JR
-6.8%
3/13 Form 3 CORCEPT THERAPEUTICS For: Mar 12 Filed by: Alton Gregg H -6.4%
11/7 Corcept Therapeutics Incorporated (CORT) Q3 2019 Earnings Call Transcript [The Motley Fool] -5.4%
2/28 Corcept Therapeutics Incorporated (NASDAQ: CORT) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. -5.1%
5/9 Q1/2019 3/31/2019 EPS 0.200 ZacksConsensus 0.180 ActVsEst 0.020 - Beat -5.1%
1/30 Form 8-K CORCEPT THERAPEUTICS For: Jan 30 -4.6%
3/12 Corcept Therapeutics Appoints Gregg Alton to Board of Directors -4.4%
8/20 Corcept Therapeutics Incorporated (NASDAQ: CORT) was upgraded by analysts at TheStreet from a "c+" rating to a "b" rating. -3.9%
4/27 Form DEF 14A CORCEPT THERAPEUTICS For: Apr 27 -3.5%
6/5 Form 4 CORCEPT THERAPEUTICS For: Jun 03 Filed by: BAKER G LEONARD JR -2.7%
3/13 Form 3 CORCEPT THERAPEUTICS For: Mar 12 Filed by: Alton Gregg H -6.4%
11/7 Corcept Therapeutics Incorporated (CORT) Q3 2019 Earnings Call Transcript [The Motley Fool] -5.4%
2/28 Corcept Therapeutics Incorporated (NASDAQ: CORT) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. -5.1%
5/9 Q1/2019 3/31/2019 EPS 0.200 ZacksConsensus 0.180 ActVsEst 0.020 - Beat -5.1%
1/30 Form 8-K CORCEPT THERAPEUTICS For: Jan 30 -4.6%
3/12 Corcept Therapeutics Appoints Gregg Alton to Board of Directors -4.4%
8/20 Corcept Therapeutics Incorporated (NASDAQ: CORT) was upgraded by analysts at TheStreet from a "c+" rating to a "b" rating. -3.9%
4/27 Form DEF 14A CORCEPT THERAPEUTICS For: Apr 27 -3.5%
6/5 Form 4 CORCEPT THERAPEUTICS For: Jun 03 Filed by: BAKER G LEONARD JR -2.7%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: